You are not logged in.

Survivin modulators: an updated patent review (2011-2015)

Roy, Kislay, Singh, Neha, Kanwar, Rupinder K. and Kanwar, Jagat R. 2016, Survivin modulators: an updated patent review (2011-2015), Recent patents on anti-cancer drug discovery, vol. 11, no. 2, pp. 152-169, doi: 10.2174/1574892811666160229121815.


Title Survivin modulators: an updated patent review (2011-2015)
Author(s) Roy, Kislay
Singh, Neha
Kanwar, Rupinder K.
Kanwar, Jagat R.
Journal name Recent patents on anti-cancer drug discovery
Volume number 11
Issue number 2
Start page 152
End page 169
Total pages 18
Publisher Bentham Science Publishers
Place of publication Beijing, China
Publication date 2016
ISSN 2212-3970
Keyword(s) amino acid sequence
animals
antineoplastic agents
humans
inhibitor of apoptosis proteins
neoplasms
patents as topic
protein structure, secondary
taxoids
cancer
clinical
patent
survivin
therapeutic
Summary BACKGROUND: Survivin is widely overexpressed in many forms of cancer and studies have related high survivin expression with poor survival rates. Although, there have been several attempts to target survivin, most therapeutics haven't shown substantial success in clinical trials therefore, authors wish to attract the focus towards many recent therapeutic innovations to target survivin. OBJECTIVE: Survivin plays an essential role in the cell cycle progression, apoptosis, cell stress response, drug resistance and angiogenesis therefore the prognostic and targeting benefits of survivin have been underestimated. An update on the current and existing therapeutic strategies implemented to target survivin is provided. Therefore, the reader will gain an insight into the recent patents targeting survivin. The review has emphasised on patents for quantification of survivin, survivin peptides as immunotherapeutics, application of survivin promoters, RNA interference of survivin, small molecules inhibitors of survivin and nanoparticles targeting survivin. The review also encompasses the survivin targeted therapeutics being implemented at clinical stages which include survivin targeted immunotherapeutics, peptide-based vaccines, antisense oligonucleotides and chemical inhibitors. CONCLUSION: We reviewed recent patents based on preclinical anti-survivin therapies reported to date and it was concluded that gataparsen has been most widely used for anti-survivin therapy in clinical trials. It was also concluded that most therapeutic patents were focussed on development of natural anti-survivin therapeutics such as anti-survivin peptides or survivin anti-sense oligonucleotides in the recent years therefore, proving that natural proteins and nucleic acids has an upper hand over chemicals and synthetic drugs.
Language eng
DOI 10.2174/1574892811666160229121815
Field of Research 111299 Oncology and Carcinogenesis not elsewhere classified
0601 Biochemistry And Cell Biology
1112 Oncology And Carcinogenesis
Socio Economic Objective 970111 Expanding Knowledge in the Medical and Health Sciences
HERDC Research category C1 Refereed article in a scholarly journal
ERA Research output type C Journal article
Copyright notice ©2016, Bentham Science Publishers
Persistent URL http://hdl.handle.net/10536/DRO/DU:30087410

Document type: Journal Article
Collection: School of Medicine
Connect to link resolver
 
Unless expressly stated otherwise, the copyright for items in DRO is owned by the author, with all rights reserved.

Versions
Version Filter Type
Citation counts: TR Web of Science Citation Count  Cited 2 times in TR Web of Science
Scopus Citation Count Cited 2 times in Scopus
Google Scholar Search Google Scholar
Access Statistics: 41 Abstract Views  -  Detailed Statistics
Created: Thu, 13 Oct 2016, 13:56:31 EST

Every reasonable effort has been made to ensure that permission has been obtained for items included in DRO. If you believe that your rights have been infringed by this repository, please contact drosupport@deakin.edu.au.